REAL-WORLD (RW) DISEASE PROGRESSION AND HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE UNITED STATES (US)
Author(s)
Damemarie Paul, MPH, DrPH1, Emily Gao, MS, MPH2, Annika Anderson, MPH2, Debbie Goldschmidt, PhD2, Elyse Swallow, MA, MPP2, Phillip Hivale, PharmD, MBA1, Paul Cockrum, PharmD1, Jay Jackson, PharmD, MPH1;
1Vera Therapeutics, Brisbane, CA, USA, 2Analysis Group, Inc., Boston, MA, USA
1Vera Therapeutics, Brisbane, CA, USA, 2Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: IgAN is a chronic B-cell mediated autoimmune disease-causing progressive, irreversible kidney injury and substantial, long-term healthcare utilization. This retrospective analysis of US administrative claims quantified disease progression and HCRU among a RW cohort of IgAN patients with kidney biopsy.
METHODS: US claims and laboratory results from Komodo Research Data (01/2020 to 12/2024) included patients with ≥1 IgAN diagnosis and kidney biopsy ≤6 months before or ≤30 days after first diagnosis (index). Patients were ≥18 years at index, had ≥6 months of continuous enrollment pre-index (baseline), and were followed until the end of continuous enrollment, data availability, or death (post-index). Patient characteristics were summarized during baseline/at index. Treatment use was summarized post-index. eGFR reduction was summarized among patients with eGFR data during baseline and within 1-year post-index. All-cause post-index HCRU were summarized per patient per year (PPPY).
RESULTS: Overall, 5,850 patients were included with a mean (SD) post-index observation period of 18 (13) months. At index, mean (SD) age was 47 (16) years. Most patients were male (57%), had commercial insurance (68%), and had substantial disease severity and comorbidity burden, including CKD stage ≥3 (55%), cardiovascular disease (79%), and hypertension (73%). Post-index, most patients received renin-angiotensin-aldosterone system inhibitors (79%), corticosteroids (61%) and/or sodium-glucose cotransporter-2 inhibitors (28%). Despite treatment, HCRU remained high with mean (SD) rates of 1.0 (2.7) inpatient admissions, 39.4 (46.7) outpatient visits, and 1.4 (4.5) emergency department visits PPPY. Inpatient length of stay was 10.8 (36.1) days PPPY. Among patients with available eGFR data (N=340), mean baseline eGFR was 55.2 mL/min/1.73 m² and declined by an average of 12.3% over one year.
CONCLUSIONS: This RW IgAN population experienced significant kidney function decline and high annual HCRU despite available treatment, highlighting the need for novel effective treatment options that slow disease progression and reduce the associated healthcare burden.
METHODS: US claims and laboratory results from Komodo Research Data (01/2020 to 12/2024) included patients with ≥1 IgAN diagnosis and kidney biopsy ≤6 months before or ≤30 days after first diagnosis (index). Patients were ≥18 years at index, had ≥6 months of continuous enrollment pre-index (baseline), and were followed until the end of continuous enrollment, data availability, or death (post-index). Patient characteristics were summarized during baseline/at index. Treatment use was summarized post-index. eGFR reduction was summarized among patients with eGFR data during baseline and within 1-year post-index. All-cause post-index HCRU were summarized per patient per year (PPPY).
RESULTS: Overall, 5,850 patients were included with a mean (SD) post-index observation period of 18 (13) months. At index, mean (SD) age was 47 (16) years. Most patients were male (57%), had commercial insurance (68%), and had substantial disease severity and comorbidity burden, including CKD stage ≥3 (55%), cardiovascular disease (79%), and hypertension (73%). Post-index, most patients received renin-angiotensin-aldosterone system inhibitors (79%), corticosteroids (61%) and/or sodium-glucose cotransporter-2 inhibitors (28%). Despite treatment, HCRU remained high with mean (SD) rates of 1.0 (2.7) inpatient admissions, 39.4 (46.7) outpatient visits, and 1.4 (4.5) emergency department visits PPPY. Inpatient length of stay was 10.8 (36.1) days PPPY. Among patients with available eGFR data (N=340), mean baseline eGFR was 55.2 mL/min/1.73 m² and declined by an average of 12.3% over one year.
CONCLUSIONS: This RW IgAN population experienced significant kidney function decline and high annual HCRU despite available treatment, highlighting the need for novel effective treatment options that slow disease progression and reduce the associated healthcare burden.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE190
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Urinary/Kidney Disorders